No Data
No Data
Citi Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $60
Structure Draws New Buy at Citi on Oral Obesity Drug Pipeline
Citigroup Initiates Coverage on Structure Therapeutics With Buy Rating, $60 Price Target
Viking Among Notable Gainers as Pfizer Raises Deal Prospects
H.C. Wainwright Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $80
Structure Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.